Are Prostate Biopsies Dangerous? Risks and Complications

Prostate biopsies carry real but generally manageable risks, and the vast majority of men go home the same day without serious complications. In large datasets, fewer than 3% of biopsies lead to a hospital admission, with infection and significant bleeding being the main culprits. That said, how the biopsy is performed, what antibiotics you receive, and your individual health profile all shift the odds enough to be worth understanding before you’re on the table.

How Often Do Serious Complications Happen

The word “dangerous” covers a lot of ground, so it helps to separate common-but-harmless side effects from rare-but-serious events. Blood in the urine, stool, or semen after a biopsy is extremely common. A systematic review covering multiple large series found that hematuria and blood in the semen are typical after the procedure but almost always mild and self-limiting, while severe rectal bleeding is uncommon.¹ In a prospective study of men who could ejaculate after biopsy, about 90% had blood in their semen, lasting an average of four weeks.² That number sounds alarming until you understand it usually resolves on its own and doesn’t signal anything harmful.

Hospitalization is the clearest marker of a serious complication. In one prospective series, about 3.6% of patients required hospital admission, with the reasons split between sepsis and heavy rectal bleeding.³ A Medicare analysis of U.S. fee-for-service patients found that inpatient admissions added roughly $13,840 to biopsy costs but occurred in only about 2.8% of cases.⁴ So the baseline picture is reassuring for most men, but the consequences when things do go wrong can be significant.

Infection Is the Biggest Concern

Infection after prostate biopsy is the complication urologists worry about most, because it can escalate to sepsis. The traditional approach sends the biopsy needle through the rectal wall, which means every pass drags gut bacteria into the prostate and surrounding tissue. Antibiotic prophylaxis is standard, but when the bacteria in a man’s rectum are resistant to the antibiotics given, the protection breaks down. At one tertiary center in Lebanon, the urosepsis rate after transrectal biopsy reached 9.4%, with most cases involving drug-resistant E. coli.⁵ That figure is at the high end of published rates, but it illustrates how the risk is not uniform across all settings.

The bacteria in your rectum matter more than most patients realize. Fluoroquinolones like ciprofloxacin have been the traditional prophylactic antibiotics, and resistance to them has climbed steadily. One screening study found fluoroquinolone-resistant organisms in 22% of patients before their transrectal biopsy.⁶ A prospective study found that the degree of fluoroquinolone resistance in rectal E. coli was the dominant risk factor for developing a urinary tract infection with signs of systemic inflammation after biopsy, more so than any other patient characteristic.⁷ Men carrying resistant bacteria who only received fluoroquinolone prophylaxis had infection rates around 8% and hospitalization rates above 6%.⁸

An unusual environmental factor also appears to matter: ambient temperature. A study of transrectal biopsies found that infection rates were significantly higher in summer than in winter, with urinary tract infections, sepsis, and other infectious complications increasing by roughly 12–21% for every one-degree Celsius rise in average monthly temperature.⁹ The likely explanation is that warmer weather shifts the composition of rectal flora in ways that favor resistant organisms, though the practical takeaway is modest since no one schedules a biopsy around the weather forecast.

Transperineal Versus Transrectal Biopsy

The single biggest shift in prostate biopsy safety in recent years is the move toward the transperineal approach, which sends the needle through the skin between the scrotum and the anus rather than through the rectum. By bypassing the bowel entirely, this route dramatically cuts the risk of introducing gut bacteria into the prostate. In the PREVENT randomized trial, zero patients in the transperineal group developed infections compared to six in the transrectal group.¹⁰ A companion analysis of the same trial design published in European Urology reported zero transperineal infections versus four transrectal infections.¹¹

Real-world data from a Middle Eastern center showed a similar pattern: the infection rate was 4.1% for transrectal biopsies compared to 1.2% for transperineal.¹² This has led the PREVENT trial investigators to conclude that transperineal biopsy should be the standard of care. Many centers have already made the switch, though transrectal biopsies are still performed widely, especially where the equipment or training for transperineal access is less available. If you have a choice, asking about a transperineal approach is reasonable.

Can Rectal Swabs Prevent Post-Biopsy Infections

For transrectal biopsies, one strategy to address the antibiotic-resistance problem is to swab the rectum before the procedure and culture the bacteria. If resistant organisms show up, the prophylactic antibiotic can be tailored accordingly. A multicenter randomized trial tested this culture-guided approach against standard empirical prophylaxis and found that infection rates within seven days dropped from about 4.3% with empirical antibiotics to about 2.5% with targeted ones. After adjusting for other factors, the odds of infection roughly halved.¹³

The picture is not entirely simple, however. Another study that used augmented prophylaxis guided by rectal swabs found that the overall sepsis rate did not change significantly between groups. Men with ciprofloxacin-resistant rectal flora still had a substantially higher rate of sepsis regardless, suggesting the swab-based approach helps but does not eliminate the problem entirely.¹⁴ Some institutions now use rectal swabs routinely before transrectal biopsies; others view the shift to transperineal access as the more definitive solution.

Bleeding and Blood Thinners

Some amount of bleeding after prostate biopsy is essentially guaranteed. The important questions are how much and whether blood-thinning medications make it dangerously worse. A study that compared men on warfarin, low-dose aspirin, and no blood thinners found hematuria in about 28–38% across all three groups, rectal bleeding in 12–14%, and blood in the semen in 7–14%. There were no severe bleeding complications in any group. Regression analysis showed a significant link between the number of biopsy cores taken and bleeding, but no significant link between warfarin use and minor bleeding events.¹⁵

For aspirin specifically, a trial comparing men who continued aspirin to those who stopped found no significant difference in the duration of blood in the urine, rectal bleeding, or blood in the semen.¹⁶ That result matters because stopping aspirin in a man with heart disease carries its own risks. The current trend in urology is to let low-dose aspirin continue, though decisions about other anticoagulants and dual-therapy regimens are handled case by case. When antithrombotic agents are continued, the odds of grade 2 or higher bleeding roughly double compared to controls, so it isn’t risk-free.¹⁷

Urinary Retention After Biopsy

Temporary inability to urinate is one of those complications that nobody warns you about until it happens. In a large retrospective series of over 8,000 transrectal biopsies, urinary retention accounted for about 35% of all non-infectious complications. The strongest predictor was simply having a larger prostate: for every 5 cc increase in gland size, the odds of retention went up by about 7%.¹⁸

The transperineal approach does not eliminate this risk. In a tertiary-center study of freehand transperineal biopsies, about 14% of patients experienced retention within 24 hours. Retention was significantly more common in men with prostate volumes above roughly 58 cc and in those who had more than 23 cores taken.¹⁹ If you already have trouble emptying your bladder or know your prostate is enlarged, this is worth discussing with your urologist beforehand, since catheterization may be needed for a day or two.

Effects on Sexual Function

Men are understandably concerned about what a biopsy will do to their erections. A systematic review and meta-analysis found that erectile function scores dip by about two points on a 25-point questionnaire at one month after biopsy but return to baseline by three months on average.²⁰ In practical terms, most men notice some decrease in erectile quality for a few weeks but recover fully.

The exception may be men on active surveillance who undergo repeated biopsies over time. A study tracking men through serial transperineal biopsies found a sharp drop in erectile function scores at one month after the first biopsy, with full recovery by six months. But after the second biopsy, recovery was slower and potentially incomplete, suggesting that repeat procedures may carry cumulative effects that a single biopsy does not.²¹ One smaller prospective study even found progressive decline in erectile function scores through six months after a single transrectal biopsy, though this contrasts with the larger meta-analysis and may reflect patient anxiety as much as physical damage.²²

How Much Does It Hurt

Pain during prostate biopsy varies widely depending on how much local anesthesia is used. Without any nerve block, most men describe the discomfort as tolerable but unpleasant. The standard technique is a periprostatic nerve block, where lidocaine is injected near the nerves at the base of the prostate, and studies consistently show this reduces pain scores significantly compared to no block at all.²³ Some practitioners add an additional injection at the prostate apex, and evidence suggests this further improves comfort, particularly during targeted biopsies of specific lesions.²⁴

Transperineal biopsies are sometimes performed under sedation or general anesthesia, especially when many cores are needed, though increasingly they’re done with local anesthesia in clinic. If you’re especially anxious about pain, it’s worth asking your urologist what level of anesthesia they plan to use, since practice varies between centers.

Who Is at Higher Risk for Complications

Some men face elevated odds of trouble, and the risk factors are identifiable ahead of time. A multivariate analysis found that higher body mass index, a history of diabetes, and having a catheter in place before the procedure were all independent risk factors for post-biopsy infection.²⁵ Interestingly, a separate large retrospective study of nearly 1,900 cases found that age, common underlying diseases like hypertension and heart disease, and even the use of blood thinners were not significantly associated with major complications, suggesting the infection pathway is more variable than the bleeding one.²⁶

The number of cores taken is a perennial concern among patients. As noted in the retention discussion, more cores mean more swelling. However, an older comparison of protocols using 6, 10, and 15 cores found that increasing the sample count did not increase overall post-biopsy morbidity.²⁷ That said, saturation biopsies with 20 or more cores may be a different story, particularly for retention risk.

The Psychological Side

Physical complications get the most attention, but the psychological impact is substantial and underappreciated. Nearly half of men in one study reported significant biopsy-related distress. Distress was highest in men whose result came back as cancer, where the odds of significant distress tripled compared to those with a negative result. Even men with indeterminate findings, where the biopsy was inconclusive, had more than double the odds of distress compared to those who got a clear negative.²⁸

Anxiety and physical symptoms feed on each other. In a study tracking men with negative biopsies, those who experienced troublesome symptoms like pain, blood in the urine, or rectal bleeding had significantly more anxiety at one week. By five weeks, anxiety had decreased even though the symptoms often had not, suggesting the initial shock of the experience drives the distress as much as the symptoms themselves.²⁹ A positive biopsy result also correlated with increased anxiety scores, and men with very high PSA values were particularly affected.³⁰ This is worth knowing because some of the anxiety may be preventable through better pre-procedure counseling about what to expect.

Can You Avoid the Biopsy Altogether

For some men, the answer is genuinely yes, at least for now. MRI of the prostate has emerged as a strong triage tool. In low-risk men, the combination of a negative MRI and prostate volume measurements has a negative predictive value close to 98%, meaning that skipping the biopsy in these patients would miss very few clinically significant cancers.³¹

Blood- and urine-based biomarkers are also being used increasingly as an intermediate step. Tests beyond basic PSA can improve the prediction of whether a man harbors clinically significant cancer, and current validation data suggest these assays could spare roughly 15–50% of unnecessary biopsies while still catching 90–95% of important cancers.³² The combination of better imaging and better blood tests means the era of “biopsy everyone with a raised PSA” is ending, and men are increasingly being directed to biopsy only when there’s a reasonable probability of finding something that matters.

This shift matters because prostate cancer screening itself detects some low-risk tumors that would never have caused symptoms, and the downstream treatments for those cancers carry their own side effects.³³ Avoiding an unnecessary biopsy avoids not only the procedure’s risks but also the cascade of anxiety and possible overtreatment that follows an incidental finding.

What Complications Actually Cost

The financial dimension doesn’t always cross a patient’s mind before the procedure, but the numbers are striking. A Medicare analysis found that an uncomplicated biopsy episode cost an average of about $1,740. When at least one complication occurred, that average jumped to roughly $4,060, an increase of $2,320. The rare cases requiring inpatient admission added nearly $14,000.⁴ In the UK’s NHS, a decade-long analysis showed that unplanned readmission costs after transrectal biopsies far exceeded those after transperineal biopsies, with estimated per-patient readmission costs of about £2,225 versus £1,758 respectively.³⁴ These figures add a system-level argument to the clinical case for switching to the transperineal route and using better patient selection tools to avoid biopsies that were never needed in the first place.